Gilead inks $100M partnership with Assembly Bio for antivirals
Gilead will pay $100 million upfront for the deal, which will involve developing therapies for herpes simplex virus and hepatitis B virus.
Source: mmm-online.com
Page 4 - Assembly Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Assembly Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Assembly Bio Today - Breaking & Trending Today
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...
Source: marketscreener.com
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif.,...
Source: marketscreener.com
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL's International Liver Congress™ 2023
SOUTH SAN FRANCISCO, Calif., June 21, 2023 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today... | June 21, 2023
Source: marketscreener.com